Proteomic signatures during pregnancy: an exploratory cohort study of long-term health indicators.

IF 11.2 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
EBioMedicine Pub Date : 2026-10-01 Epub Date: 2026-09-22 DOI:10.1016/j.ebiom.2026.106491
Lucy A Bartho, Susan P Walker, Teresa MacDonald, Danica Idzes, Ping Cannon, Tuong-Vi Nguyen, Gordon Smith, D Stephen Charnock-Jones, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino
{"title":"Proteomic signatures during pregnancy: an exploratory cohort study of long-term health indicators.","authors":"Lucy A Bartho, Susan P Walker, Teresa MacDonald, Danica Idzes, Ping Cannon, Tuong-Vi Nguyen, Gordon Smith, D Stephen Charnock-Jones, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino","doi":"10.1016/j.ebiom.2026.106491","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pregnancies complicated by fetal growth restriction (FGR) and preeclampsia are associated with increased long-term chronic disease risk. A blood test could possibly identify those at risk, opening the door to early interventions soon after delivery. Prior work in non-pregnant people have identified protein signatures associated with 18 different health parameters, called SomaSignal Tests.</p><p><strong>Methods: </strong>This study applied SomaSignal tests to plasma samples collected in pregnancy from two independent cohorts to assess the 18 health parameters in those who later developed FGR and preeclampsia. SomaScan Assay measured ∼7000 modified aptamers in plasma from two independent cohorts. Plasma samples (Melbourne, Australia) were collected at 36 weeks' gestation from women who later delivered an FGR infant (<3rd birthweight centile, n = 118), preeclampsia at term (n = 92) or did not develop either condition (n = 177). The second cohort (Cambridge, UK) were plasma samples collected at 36 weeks' gestation from women who later delivered an FGR infant (n = 80), and those who did not (n = 172).</p><p><strong>Findings: </strong>In the Australian cohort, women who later delivered growth-restricted infants had composite protein signatures associated with reduced cardiac function (p = 0.001), increased cardiovascular events (p = 7.6 × 10<sup>-6</sup>), mid-life dementia (p = 1.5 × 10<sup>-9</sup>), and higher visceral fat (p = 4.06 × 10<sup>-6</sup>), compared to pregnancies without complications. Findings were largely consistent in both Australian and UK sample sets. Those who developed preeclampsia had protein signatures signifying cardiovascular (p = 5.54 × 10<sup>-6</sup>), hepatic (p = 0.001), and renal (p = 0.0007) disease risks, compared to pregnancies without complications.</p><p><strong>Interpretation: </strong>Since signatures were more pronounced in pregnancies that were later diagnosed with FGR and preeclampsia, underlying physiological changes may have been present before diagnosis. These changes result in protein signatures concordant with those associated with poor long-term health outcomes in non-pregnant populations. These associations require validation in large, longitudinal cohorts investigating pregnancy, with long-term maternal follow-up.</p><p><strong>Funding: </strong>Stillbirth CRE, Mercy Hospital Foundation and National Health and Medical Research Council, Royal Australian and New Zealand College of Obstetricians and Gynaecologists, Taylor Hammond Scholarship, National Health and Medical Research Council Fellowships and Australian Research Council Future Fellowships.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"132 ","pages":"106491"},"PeriodicalIF":11.2000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13638798/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EBioMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ebiom.2026.106491","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pregnancies complicated by fetal growth restriction (FGR) and preeclampsia are associated with increased long-term chronic disease risk. A blood test could possibly identify those at risk, opening the door to early interventions soon after delivery. Prior work in non-pregnant people have identified protein signatures associated with 18 different health parameters, called SomaSignal Tests.

Methods: This study applied SomaSignal tests to plasma samples collected in pregnancy from two independent cohorts to assess the 18 health parameters in those who later developed FGR and preeclampsia. SomaScan Assay measured ∼7000 modified aptamers in plasma from two independent cohorts. Plasma samples (Melbourne, Australia) were collected at 36 weeks' gestation from women who later delivered an FGR infant (<3rd birthweight centile, n = 118), preeclampsia at term (n = 92) or did not develop either condition (n = 177). The second cohort (Cambridge, UK) were plasma samples collected at 36 weeks' gestation from women who later delivered an FGR infant (n = 80), and those who did not (n = 172).

Findings: In the Australian cohort, women who later delivered growth-restricted infants had composite protein signatures associated with reduced cardiac function (p = 0.001), increased cardiovascular events (p = 7.6 × 10-6), mid-life dementia (p = 1.5 × 10-9), and higher visceral fat (p = 4.06 × 10-6), compared to pregnancies without complications. Findings were largely consistent in both Australian and UK sample sets. Those who developed preeclampsia had protein signatures signifying cardiovascular (p = 5.54 × 10-6), hepatic (p = 0.001), and renal (p = 0.0007) disease risks, compared to pregnancies without complications.

Interpretation: Since signatures were more pronounced in pregnancies that were later diagnosed with FGR and preeclampsia, underlying physiological changes may have been present before diagnosis. These changes result in protein signatures concordant with those associated with poor long-term health outcomes in non-pregnant populations. These associations require validation in large, longitudinal cohorts investigating pregnancy, with long-term maternal follow-up.

Funding: Stillbirth CRE, Mercy Hospital Foundation and National Health and Medical Research Council, Royal Australian and New Zealand College of Obstetricians and Gynaecologists, Taylor Hammond Scholarship, National Health and Medical Research Council Fellowships and Australian Research Council Future Fellowships.

怀孕期间的蛋白质组特征:一项长期健康指标的探索性队列研究。
背景:妊娠合并胎儿生长受限(FGR)和先兆子痫与长期慢性疾病风险增加相关。血液测试可能会识别出那些有风险的人,为分娩后不久的早期干预打开大门。之前在未怀孕人群中进行的工作已经确定了与18种不同健康参数相关的蛋白质特征,称为somassignal测试。方法:本研究将somassignal检测应用于从两个独立队列中收集的妊娠血浆样本,以评估后来发展为FGR和先兆子痫的患者的18个健康参数。SomaScan Assay检测了来自两个独立队列的血浆中约7000个修饰的适体。血浆样本(澳大利亚墨尔本)收集于妊娠36周后分娩FGR婴儿的妇女(发现:在澳大利亚队列中,与无并发症的妊娠相比,后来分娩生长受限婴儿的妇女具有与心功能降低(p = 0.001),心血管事件增加(p = 7.6 × 10-6),中年痴呆(p = 1.5 × 10-9)和更高的内脏脂肪(p = 4.06 × 10-6)相关的复合蛋白特征。研究结果在澳大利亚和英国的样本中基本一致。与没有并发症的孕妇相比,发生子痫前期的孕妇有心血管(p = 5.54 × 10-6)、肝脏(p = 0.001)和肾脏(p = 0.0007)疾病风险的蛋白质特征。解释:由于这些特征在后来被诊断为FGR和子痫前期的孕妇中更为明显,潜在的生理变化可能在诊断前就已经存在。这些变化导致蛋白质特征与那些与非怀孕人群长期健康状况不佳相关的蛋白质特征一致。这些关联需要在调查妊娠的大型纵向队列中进行验证,并对产妇进行长期随访。资助:死产CRE,仁慈医院基金会和国家卫生和医学研究委员会,澳大利亚皇家和新西兰妇产科学院,泰勒哈蒙德奖学金,国家卫生和医学研究委员会奖学金和澳大利亚研究委员会未来奖学金。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
EBioMedicine
EBioMedicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
17.70
自引率
0.90%
发文量
579
审稿时长
5 weeks
期刊介绍: eBioMedicine is a comprehensive biomedical research journal that covers a wide range of studies that are relevant to human health. Our focus is on original research that explores the fundamental factors influencing human health and disease, including the discovery of new therapeutic targets and treatments, the identification of biomarkers and diagnostic tools, and the investigation and modification of disease pathways and mechanisms. We welcome studies from any biomedical discipline that contribute to our understanding of disease and aim to improve human health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书